FDA approval, fundraising, and the reality of building in healthcare according to BioticsAI founder

FDA 批准、融资与医疗创业的现实：BioticsAI 创始人的深度分享

Founders building in the healthcare space can’t just build fast and break things. Timelines stretch longer, stakes are higher, and success depends on navigating systems that reward rigor over speed. That’s exactly the reality Robhy Bustami, co-founder and CEO of BioticsAI, has been building in. 在医疗领域创业的创始人不能仅仅追求“快速行动，打破常规”。这里的项目周期更长，风险更高，成功取决于能否在那些推崇严谨胜过速度的体系中游刃有余。这正是 BioticsAI 联合创始人兼首席执行官 Robhy Bustami 一直在面对的现实。

His company is developing an AI copilot for ultrasound that helps detect fetal abnormalities, an area where misdiagnosis rates remain surprisingly high. Bustami joined Isabelle Johannessen on Build Mode to discuss how the company has navigated a highly regulated space and kept the team motivated while cutting through all the red tape. 他的公司正在开发一款用于超声检查的 AI 副驾驶系统，旨在帮助检测胎儿异常，而这一领域的误诊率依然高得惊人。Bustami 做客《Build Mode》节目，与主持人 Isabelle Johannessen 探讨了公司如何在高度监管的环境中破除重重阻碍，并保持团队的积极性。

BioticsAI started scrappy. The team built an early, functioning version of the product for under $100,000, an almost unheard of milestone in the medical device world. That prototype helped them win TechCrunch Startup Battlefield in 2023, bringing early visibility and credibility. BioticsAI 的起步非常艰苦。团队仅用不到 10 万美元就开发出了产品的早期功能版本，这在医疗器械领域几乎是闻所未闻的里程碑。正是这一原型产品帮助他们在 2023 年赢得了 TechCrunch Startup Battlefield 大赛，为公司带来了早期的知名度和信誉。

In January, they gained FDA approval, which means they can begin launching in hospitals and growing the business at a new rate. From day one, the team approached product development with FDA approval in mind. Instead of building first and figuring out regulation later, they integrated clinical validation, regulatory strategy, and product development into a single process. 今年 1 月，他们获得了 FDA 的批准，这意味着他们可以开始在医院部署产品，并以全新的速度拓展业务。从第一天起，团队在进行产品开发时就始终将 FDA 审批纳入考量。他们没有选择“先开发、后合规”的模式，而是将临床验证、监管策略和产品开发整合为一个统一的流程。

That meant working closely with clinicians, collecting large-scale datasets, and running structured clinical studies before ever reaching the submission stage. The FDA process itself is often viewed as a black box, but Bustami emphasizes that founders don’t have to navigate it blindly. Early engagement with regulators, through pre-submission meetings, helped the team align on study design and expectations. 这意味着在提交申请之前，他们必须与临床医生密切合作，收集大规模数据集，并开展结构化的临床研究。FDA 的审批流程常被视为一个“黑箱”，但 Bustami 强调，创始人不必盲目摸索。通过提交前的沟通会议与监管机构进行早期接触，帮助团队在研究设计和预期目标上达成了共识。

Still, risk never fully disappears. For many investors, the biggest question is simple: What if the FDA says no? Internally, those long timelines create a different kind of challenge: keeping a team motivated when the biggest milestone is years away. At BioticsAI, that meant building a culture of alignment across engineers, clinicians, and researchers, ensuring everyone got to see the wins that were happening. 尽管如此，风险从未完全消失。对于许多投资者来说，最大的问题很简单：如果 FDA 拒绝了怎么办？在内部，漫长的周期带来了另一种挑战：当最大的里程碑还在数年之后时，如何保持团队的动力？在 BioticsAI，这意味着要建立一种让工程师、临床医生和研究人员保持一致的文化，确保每个人都能看到公司取得的每一个进展。

“Making sure everyone is completely aligned, even if it’s outside of their technical scope,” Bustami said, “constantly seeing wins on the R&D side,” from clinical studies to new healthcare partnerships. “确保每个人都完全步调一致，即使这超出了他们的技术范畴，”Bustami 说，“要让他们不断看到研发方面的胜利”，从临床研究到新的医疗合作伙伴关系，皆是如此。

Now, with FDA clearance secured, BioticsAI is entering a new phase: deployment. The company is beginning to roll out its technology in hospitals, with plans to expand beyond obstetrics into broader areas of reproductive health. 如今，随着 FDA 许可的获得，BioticsAI 进入了一个新阶段：部署。公司正开始在医院推广其技术，并计划从产科扩展到更广泛的生殖健康领域。

Building in healthcare is a long game. It requires patience, discipline, and a willingness to operate in uncertainty. For founders willing to take that path, the reward isn’t just a successful company — it’s the chance to build something that genuinely changes how care is delivered. 医疗创业是一场持久战。它需要耐心、纪律以及在不确定性中运作的意愿。对于愿意走这条路的创始人来说，回报不仅仅是一家成功的公司，更是有机会打造出真正改变医疗服务交付方式的产品。